TSO
Commercial- Indications
- Ulcerative colitis, Crohn's disease, Multiple sclerosis, Type 1 diabetes, Asthma, Rheumatoid arthritis, Autism, Lupus, Allergies
Company intelligence / Profile preview
Tanawisa produces TSO® (Trichuris suis ova), a helminthic probiotic supplement approved by the Thai FDA since 2006. Clinical studies have shown significant improvements in inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. However, large-scale Phase II trials for Crohn's disease did not meet endpoints, which slowed further pharmaceutical development. The product remains available as a regulated supplement in some markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tanawisa Company Ltd..